Prospective, Randomized, Placebo-controlled, Multi-center Trial Comparing the Efficacy and Safety of Subcutaneous Immunotherapy With a Mixture of Grasses and Mites at Adequate Doses Versus Monotherapy, for the Treatment of Allergy
Latest Information Update: 21 Dec 2023
At a glance
- Drugs MG 01 (Primary) ; MM 09 (Primary) ; MM09-MG01 (Primary)
- Indications Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Inmunotek
- 21 Nov 2023 This study has been discontinued in Spain, according to European Clinical Trials Database record.
- 02 Aug 2022 Planned End Date changed from 1 Sep 2022 to 1 Oct 2023.
- 02 Aug 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Oct 2023.